A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to ...

Researchers from The University of Osaka identify a molecule that can support specific therapeutic targeting of AML with ...

The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.

SLS009 is associated with an improvement in survival among patients with relapsed/refractory acute myeloid leukemia.

Ziftomenib’s FDA application for relapsed/refractory NPM1-mutant acute myeloid leukemia is supported by data from the ...

Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in ...

CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to ...

Aug. 21, 2024 — An international team of scientists has uncovered a mechanism by which acute myeloid leukemia (AML) cells sustain their growth. AML cells prevent the synthesis of proteins that ...

Exicure, Inc. (Nasdaq: XCUR) today shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor. Exicure, Inc. ("Exicure") is planning for a clinical trial in Acute Myeloid ...

A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified ...